// App-Quantinova.ai

: MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE

Researchers

Presenter

  • Heather Miller

Principal Investigators

  • Johan K Wallman

  • Ingemar Petersson

  • Saedis Saevarsdottir

  • Jonas Sderling

  • Sofia Ernestam

  • Johan Askling

  • Ronald van Vollenhoven

  • Martin Neovius

Medical Centers

  • Karolinska Institutet, Department of medicine, Stockholm, Sweden

  • Lund University, Cardiology, Clinical Sciences, Lund, Sweden

  • Lund University, Cardiology, Clinical Sciences, Lund, Sweden

  • Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden

  • Academic Specialist Centre, Stockholm Health Services, Stockholm, Sweden

Locations

  • Sweden

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Infliximab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multiple Arm

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved